Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program

Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program

Shots:

  • Gilead entered into a strategic collaboration with Glympse Bio to utilize Glympse’s technology, Glympse Inside in its NASH program to diagnose the stage of NASH as well as early detection of treatment response
  • The focus of the collaboration is to meet highly unmet medical needs and to improve the lives of patients by transforming the disease detection and measuring treatment response
  • Glympse Inside is a pan-disease product engine focusing on transforming disease monitoring and treatment response by integrating synthetic biomarkers with machine learning and AI

Click here to­ read full press release/ article | Ref: Gilead | Image: The Economic Times